TB-500 Dosage Guide: Protocols, Calculator & Safety

Dose Range

2000-5000 mcg (2-5 mg) subcutaneous 2x weekly loading; 2000 mcg (2 mg) weekly maintenance

Frequency

2x per week during loading; 1x per week maintenance

Cycle Length

4–8 weeks loading, then 2–4 weeks maintenance

Half-Life

Plasma half-life is short - full-length thymosin beta-4 clears on the order of hours, while the short LKKTETQ actin-binding fragment clears within minutes. Tissue-level regenerative effects persist substantially longer than plasma exposure.

Commonly paired with BPC-157 (the "Wolverine stack"). The evidence for the pair is one rat Achilles tendon study of BPC-157 with a product the authors call synthetic thymosin beta-4 (TB-500), in which the combination added nothing over either peptide alone (PMID: 42542926), and one uncontrolled knee-pain series that combined BPC-157 with thymosin beta-4 in four of sixteen patients, form unstated (PMID: 34324435); the FDA file also holds a FAERS report of significant adverse reactions after a BPC-157 plus TB-500 research vial, causality not established. Pairing with GHK-Cu rests on mechanism alone; no study of that pair was located. The Tissue Repair Bench lays the evidence out name by name, without dosing.

Related Compounds - TB-500 is most commonly stacked with BPC-157 but appears in broader tissue-regeneration protocols: GHK-Cu for collagen remodeling, MOTS-c for mitochondrial support during high-repair phases, IGF-1 LR3 for local anabolism, and the CJC-1295 + Ipamorelin GH stack for systemic IGF-1 elevation. Senolytic adjuncts: Fisetin and the Dasatinib + quercetin combo are proposed on mechanism for chronic-injury sites; no study of any of these with TB-500 was located.

Reconstitute with bacteriostatic water. A 5mg vial with 1mL BAC water = 5mg per mL. TB-500 is systemic and does not need to be injected near the injury site. Store reconstituted vials refrigerated (2–8°C) and use within 3–4 weeks.